News

“The signing of this agreement builds upon previous manufacturing work through which fundamental cGMP processing parameters for L-DOS47 have been developed,” said John Docherty, Helix’s vice president of

Pertuzumab or 2C4 is the first in a new class of investigational agents known as HER dimerization inhibitors (HDIs). Pertuzumab is designed to bind to the HER2 receptor

These agreements follow a master settlement Lilly entered into in June 2005 that covered approximately 8,000 claimants in the US, as well as additional settlements of approximately 2,500

“The filing of HIF-1alpha, our fourth IND submission in 2006, demonstrates our strong commitment to delivering on our promises and developing a differentiated cancer portfolio,” said Jeffrey Buchalter,

The MGX-006 program is being supported via a co-development agreement between Victory and its technology partner signed in August of 2006. “Many patients who experience pain also experience

The research collaboration will include ETI-211, an HP antibody for the treatment of MRSA infections. Under the terms of the agreement Elusys and Pfizer will collaborate on determining

Cethrin was designed to specifically target the cellular response to an acute spinal cord injury (SCI), promote the re-growth of injured axons, and restore sensory and motor function.

The broad partnership centers on five drug candidates that Synosis will acquire from Roche, including four phase I molecules, which target the central nervous system. Roche had discontinued

Syntonix technology has the potential to enhance the delivery of biopharmaceuticals through less frequent injections or by enabling pulmonary delivery. Syntonix’s lead product, FIX:Fc, is a being developed